(Q68208874)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1631611%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

title

The impact of recombinant human erythropoietin on medical care costs for hemodialysis patients in Canada (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1631611%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

1 reference

0 references

history and philosophy of science

1 reference

https://api.crossref.org/works/10.1016/0277-9536(92)90129-E

18 October 2022

author name string

S. Sheingold

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1631611

18 October 2022

D. Churchill

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1631611

18 October 2022

N. Muirhead

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1631611

18 October 2022

A. Laupacis

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1631611

18 October 2022

R. Labelle

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1631611

18 October 2022

R. Goeree

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1631611

18 October 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1631611

18 October 2022

publication date

1 May 1992

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1631611%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

22 September 2019

https://api.elsevier.com/content/article/PII:027795369290129E?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0277-9536(92)90129-E

https://api.elsevier.com/content/article/PII:027795369290129E?httpAccept=text/plain

18 October 2022

1 reference

https://api.crossref.org/works/10.1016/0277-9536(92)90129-E

Social Science and Medicine

18 October 2022

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1631611%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

volume

34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1631611%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

page(s)

983-991

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1631611%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1631611%20AND%20SRC:MED&resulttype=core&format=json

Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial

22 September 2019

cites work

1

1 reference

https://api.crossref.org/works/10.1016/0277-9536(92)90129-E

The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin

18 October 2022

2

1 reference

https://api.crossref.org/works/10.1016/0277-9536(92)90129-E

Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group

18 October 2022

3

1 reference

https://api.crossref.org/works/10.1016/0277-9536(92)90129-E

Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial

18 October 2022

5

1 reference

https://api.crossref.org/works/10.1016/0277-9536(92)90129-E

Treatment of the anemia of progressive renal failure with recombinant human erythropoietin

18 October 2022

6

1 reference

https://api.crossref.org/works/10.1016/0277-9536(92)90129-E

Recombinant human erythropoietin: factors to consider in cost-benefit analysis

18 October 2022

8

1 reference

https://api.crossref.org/works/10.1016/0277-9536(92)90129-E

Should donor blood be screened for elevated alanine aminotransferase levels? A cost-effectiveness analysis

18 October 2022

13

1 reference

https://api.crossref.org/works/10.1016/0277-9536(92)90129-E

Special report: transfusion risks

18 October 2022

14

1 reference

https://api.crossref.org/works/10.1016/0277-9536(92)90129-E

Transfusion-associated hepatitis and AIDS. What is the risk?

18 October 2022

15

1 reference

https://api.crossref.org/works/10.1016/0277-9536(92)90129-E

Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin

18 October 2022

21

1 reference

https://api.crossref.org/works/10.1016/0277-9536(92)90129-E

Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study

18 October 2022

22

1 reference

https://api.crossref.org/works/10.1016/0277-9536(92)90129-E

18 October 2022

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1631611%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

1 reference